Crofelemer is promising for the treatment for patients with diarrhoea-predominant irritable bowel syndrome

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1590, 2007-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effective management of diarrhoea-predominant irritable bowel syndrome (IBS) reduces time lost from work

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 341, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Alosetron Reduces Time Lost from Work in Women with Diarrhoea-Predominant Irritable Bowel Syndrome: Data from Phase III Placebo-Controlled Clinical Trials

By Jhingran P. decker C. Watson M. Northcutt A. Ricci J-F.

Clinical Drug Investigation, Vol. 21, Iss. 12, 2001-12 ,pp. : 843-852

Adis International

Access to resources Recommend Favorite

Lubiprostone: In Constipation-Predominant Irritable Bowel Syndrome

By Carter Natalie J. Scott Lesley J.

Drugs, Vol. 69, Iss. 9, 2009-06 ,pp. : 1229-1237

Adis International

Access to resources Recommend Favorite

Rifaximin for the treatment of irritable bowel syndrome

By Cremonini Filippo Lembo Anthony

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 3, 2012-02 ,pp. : 433-440

Informa Healthcare

Access to resources Recommend Favorite

Asimadoline in the treatment of irritable bowel syndrome

By Mangel Allen W Williams Valerie SL

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 10, 2010-10 ,pp. : 1257-1264

Informa Healthcare

Access to resources Recommend Favorite